Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission
Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeting
Read more at globenewswire.comThis article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.